Luminex Plc · CSELK:LUMX.N0000
Luminex — FY2019 Earnings Presentation
10 slides from Luminex's earnings presentation, Feb 10, 2020
Slide 1: Q4 and Full-Year 2019 Conference Call Investor Presentation
Q4 and FULL-YEAR 2019 CONFERENCE CALL INVESTOR PRESENTATION February 10, 2020
Slide 2: Safe Harbor Statement
SAFE HARBOR STATEMENT Certain statements made during the course of this presentation may not be purely historical and consequently may be forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements made regarding: our
Slide 3: Overview 2019
OVERVIEW 2019 Note: all figures approximate $335M MOLECULAR LIFE SCIENCE & DIAGNOSTICS CLINICAL TOOLS (M Dx) (TOOLS) $137M $194M LICENSED FLOW AUTOMATED NON-AUTOMATED TECHNOLOGIES CYTOMETRY $76M $61M GROUP (LTG) $149M $45M complexity simplified. Recurring revenue items 3
Slide 4: Innovation, Execution, New Products
INNOVATION, EXECUTION, NEW PRODUCTS Innovative Pipeline $500M NEW PRODUCT LAUNCHES DRIVE REVENUES FROM ~$335M IN 2019 TO $500M BY 2024 Guava Next Gen System 2021 & ® xMAP INTELLIFLEX* BEYOND VERIGENE® II 2020 2020 * “SENSIPLEX” will be launching under the official name, xMAP® INTELLIFLEX 2020 comple
Slide 5: Financial Overview
FINANCIAL OVERVIEW 5
Slide 6: Significant Growth in Revenue (Ex-LabCorp)
SIGNIFICANT GROWTH IN REVENUE (EX-LABCORP) DOUBLE-DIGIT INCREASE IN ORGANIC REVENUE GROWTH (EX-LABCORP) IN 2020; LABCORP REVENUE HEADWIND OF 2% TO 3% IN 2020 $5M $16M $352M CONSISTENT $47M $319M REVENUE GROWTH $61M EX-LABCORP $55M $268M $245M (incl. 2020 guidance) $56M $48M $215M $179M $182M 2014 20
Slide 7: Revenue Growth in 2019
REVENUE GROWTH IN 2019 vs. prior vs. prior Q4 2019 2019 year year OTHER KEY Q4 2019 Revenue Sources: RESULTS: Revenue w/o LabCorp $34.4 +1% $121.2 +4% • Strong gross profit: LabCorp Revenue* $4.5 -10% $15.5 -67% 55% Total MDx Solutions Revenue $38.9 0% $136.7 -16% • Income from operations: $3.0M Flo
Slide 8: Revenue in 2020
REVENUE IN 2020 LONG-TERM REVENUE TARGET IS $500M FULL-YEAR 2020 • The company expects stronger organic growth, strong gross margins, and income and cash flow from operations • Launch in mid-2020: FULL-YEAR 2020 ‒ VERIGENE® II REVENUE GUIDANCE ‒ xMAP® INTELLIFLEX* ‒ Guava Next-Gen System $352 to $36
Slide 9: Wrap-Up
Luminex. complexity simplified. WRAP-UP
Slide 10: Luminex Investment Highlights
LUMINEX INVESTMENT HIGHLIGHTS DIVERSIFIED PRODUCT SERVING MULTI-BILLION OFFERINGS DOLLAR MARKETS • Automated & Flexible MDx Solutions • Life Science Research – Targeted • Clinical Diagnostics – Syndromic • Non-Automated MDx Solutions • Life Science and Clinical Tools STRONG BALANCE SHEET Entering a